Teplizumab's Real-World impact on diabetes delay under scrutiny
NCT ID NCT07360080
First seen Jan 26, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study follows 1,000 people with early-stage (Stage 2) Type 1 Diabetes who received teplizumab during regular doctor visits. Researchers want to see how long the treatment delays the onset of full-blown (Stage 3) diabetes and how it affects quality of life. The goal is to understand the drug's real-world benefits and risks over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Investigational Site Number: 3760001
RECRUITINGRamat Gan, 5265601, Israel
-
Investigational Site Number: 8400005
RECRUITINGSandy City, Utah, 84093, United States
Conditions
Explore the condition pages connected to this study.